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Introduction
Observational studies have shown that women receiving
hormone replacement therapy (HRT) have a reduced risk
for osteoporosis [1,2] by preventive slowing of the
decrease of bone mineral density in postmenopausal
women. Protective effects against heart disease have also
been claimed [3,4]. In contrast, Grimes and Lobo recently
reported an increased risk for cardiovascular disease and
breast cancer in the Women’s Health Initiative trial of HRT
[5]. The relation of HRT and the increased risk for breast
cancer has been controversially discussed for several
years [6,7].
It is well known that mammographic density of the breast
is increased during HRT and potentially affects the
diagnosis of breast cancer on mammograms [8,9].
Increased density may therefore obscure mammographic
masses or may decrease the detection rate of micro-
calcifications, resulting in more false-negative findings in
mammography and, consecutively, resulting in a decrease
in the sensitivity of mammographic screening [10]. Even
the specificity of mammography seems to be reduced with
postmenopausal HRT [11]. There are differences between
women using combination HRT compared with women
treated with estrogens alone [12].
CIS = carcinomas in situ; CM = contrast medium; HRT = hormone replacement therapy; MRI = magnetic resonance imaging; MRM = magnetic
resonance mammography; SI = signal intensity.
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Abstract
Background: The aim of the present article is to investigate
effects of hormone replacement therapy (HRT) on contrast
medium enhancement patterns in postmenopausal patients
during magnetic resonance mammography (MRM).
Materials and methods: Two hundred and fifteen patients
receiving hormonal medication were divided into four groups:
150 patients with 1 MRM during HRT (group A), 13 patients
with 2 MRMs under HRT (group B), 30 patients with 1 MRM
during HRT and 1 MRM after HRT withdrawal (group C), and 22
women with 1 MRM after HRT withdrawal (group D). Dynamic
MRM was performed at 1.5 Tesla. Signal intensity changes
were characterized by five time curves: minimal enhancement
(type I), weak continuous enhancement (type II), strong
continuous enhancement (type III), and a steep initial slope
followed by a plateau phenomenon (type IV) or by a washout
effect (type V).
Results: Of all 193 patients under HRT (group A + group B +
group C), 60 patients (31.1%) showed curve type I, 88 patients
(45.6%) showed type II and 45 patients (23.3%) showed type III.
There were significant differences to 52 patients after HRT
withdrawal (group C + group D) (P < 0.0001), with 42 patients
(80.8%) for curve type I, 8 patients (15.4%) for type II, and 2
patients (3.8%) for type III. In both MRM sessions in group B,
69% of the patients showed identical curve types without
significant differences (P = 0.375). In group C, 28 of 30
patients (93%) dropped to lower curve types with significant
differences in curve types during and after HRT (P < 0.0001).
Conclusion: The majority of patients receiving postmenopausal
HRT showed bilateral symmetrical, continuous enhancement
without evidence of a plateau phenomenon or a washout effect
due to HRT in MRM. Hormonal effects could be proven and
were reproducible and reversible.
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The ultrasound examination of the breast is less influenced
by HRT. It has been reported that formation of cysts
detectable by ultrasound does not significantly correlate
with HRT [13]. In women with breast tumors receiving
HRT, an increase in the number of intratumoral vessels
and an alteration of the resistance and pulsatile index were
associated with the menopausal status [14].
Several reports have described hormonal influences and
alterations of the contrast enhancement kinetics in dynamic
magnetic resonance imaging (MRI) of the breast.
Alterations in T1 and T2 relaxation times depending on the
phase of the menstrual cycle were reported in 1985 [15].
In contradiction, Martin and El Yousef did not observe
differences of the T2 relaxation time in different cycle
phases [16]. Regarding the contrast enhancement
patterns in magnetic resonance mammography (MRM), it
has been reported that during the second half of the
menstrual cycle a generally higher contrast medium (CM)
uptake of fibrocystic formations [17], and even of normal
breast parenchyma [18], takes place. Diffuse or focal
enhancement may occur in postmenopausal women who
are taking HRT [19]. Other authors report volume changes
of the breast or alterations of the tissue component such
as the ratio between fatty tissue and breast parenchyma,
the water content, and the fibroglandular fraction during
the menstrual cycle [20,21].
The purpose of the present study was to evaluate the
effects of HRT on contrast-enhancement kinetics in MRM
in postmenopausal women.
Materials and methods
Between December 1994 and April 1999, 1420 patients
who had lesions of uncertain dignity in X-ray mammo-
graphy or ultrasound of the breast underwent MRM at our
institution. The patients gave their written consent prior to
the examination. Two hundred and fifteen postmenopausal
women among these patients (mean age, 52 ± 12.2 years)
were treated with HRT. They were retrospectively divided
into four groups (groups A–D) according to the time of
onset or withdrawal of HRT and of MRM: 150 patients
received 1 MRM during HRT (group A), 13 patients
underwent 2 MRMs under HRT (group B), 30 patients
received 1 MRM during HRT and 1 MRM within 1–3 months
after HRT withdrawal (group C), and 22 women received
1 MRM within 1–3 months after withdrawal of hormonal
medication (group D) (Table 1).
All MRM studies were performed on a 1.5 Tesla magnetic
resonance scanner (ACS II; Philips, Best, The Netherlands).
Patients lay in a prone position on a dedicated double
breast coil. Subsequent to acquisition of scout images in
three orthogonal orientations, a T1-weighted two-
dimensional gradient echo sequence (repetition time/echo
time/flip angle = 12/4.1/30; thickness, 4 mm; field of view,
350 × 350 mm2; matrix, 256 × 256; seven slices;
acquisition time, 1 min and 25 s) in the coronal orientation
and a T2-weighted turbo spin echo sequence (repetition
time/echo time/flip angle = 14286/300/90; turbo factor,
29; slice thickness, 4 mm; gap, 0.4 mm; field of view,
350 × 350 mm2; matrix, 256 × 256; 24 slices; acquisition
time, 3 min and 5 s) in the transverse orientation were
acquired. Dynamic contrast-enhanced scans were
performed using a multislice, T1-weighted, two-
dimensional gradient echo sequence in the transverse
orientation (repetition time/echo time/flip angle = 96/5/80;
slice thickness, 4 mm; gap, 0.4 mm; field of view,
350 × 350 mm2; matrix, 256 × 256; 24 slices; acquisition
time, 1 min) at 1-min intervals before and after intravenous
Table 1
Patient groups according to the time of onset or withdrawal of hormone replacement therapy (HRT)
Examinations during  Examinations after 
Group HRT HRT withdrawal Data evaluation
Group A (n = 150) 1
Group B (n = 13) 2 Test for reproducibility
Group C (n = 30) 1 1 Test for effect of HRT (dependent samples)
Group D (n = 22) 1
Group A + group B,  1 Distribution of curve types under HRT
first examination + group C, 
first examination (n = 193)
Group C, second examination +  1 Distribution of curve types after HRT withdrawal
group D (n = 52)
Total (n = 215)
Two hundred and fifteen patients were divided into four groups related to the time relationship between HRT and magnetic resonance
mammography and the numbers of examinations. Examinations after HRT withdrawal were performed 1–3 months after termination.Breast Cancer Research    Vol 6 No 3 Pfleiderer et al.
R234
administration of a bolus of 0.1 mmol/kg dosage of Gd-
DTPA (Magnevist; Schering, Berlin, Germany) for 8 min.
For semiquantative analysis of the dynamic study, time–
signal intensity (SI) curves were calculated and subtraction
of the precontrast images from the postcontrast images
was performed using the built-in software of the magnetic
resonance scanner. Regions of interest were placed in
each area or spot that showed CM enhancement. Five
curve types concerning the amount of CM enhancement
were predefined according to the report of Kaiser and
Zeitler [22]. The curves were characterized by minimal
enhancement (up to 25% increase of the SI after
administration of Gd-DTPA; curve type I), weak continuous
enhancement (increase of SI between 25% and 60%;
curve type II), strong continuous enhancement (increase
of SI between 60% and 80%; curve type III), and a steep
initial slope (more than 80% increase of SI) followed by a
plateau phenomenon (curve type IV) or by a washout
effect (curve type V) (Fig. 1). Curve type IV is suspicious
and curve type V is highly suspicious for a malignant tumor
in MRM. Curve types I–III are more typical for benign
lesions [22]. In cases where several areas or spots with
different curve types were present in the same breast, the
curve type most suspicious for malignancy was chosen for
evaluation.
The Kruskal–Wallis test for single-ordered row x column
tables was used to evaluate statistical differences
between the incidence of the five curve types of all
patients examined during HRT (group A, group B and
group C) and those patients who underwent MRM without
hormonal medication (group C and group D). This test
was also used for testing whether group D, which was
examined without HRT, differed notably in its SI curve
distribution compared with all other patients receiving
HRT (group A, group B and group C) and whether group
D would thus be representative for that sample. For
statistical evaluation of differences between the curve
types achieved in the two examinations during and after
withdrawal of HRT in group C, an exact Wilcoxon signed
rank test for dependent samples was performed. The
same test was used to evaluate differences between the
two measurements during HRT in group B.
Results
Of all patients receiving HRT at the time of examination
(group A; group B, first examination; group C, first
examination), 60 of 193 patients (31.1%) showed curve
type I, 88 patients (45.6%) were referred to as curve type II,
and 45 patients (23.3%) showed curve type III (Fig. 2).
CM enhancement characteristics were homogeneous or
spotted granular, were continuous over the time of dynamic
imaging and were symmetrical in both breasts. One of the
patients with curve type II had an additional segmental
spotted granular CM enhancement according to curve
type IV in the right breast. The histological evaluation after
surgical excision revealed a ductal carcinoma in situ in the
right breast. One of the patients with curve type III
revealed a breast lesion on the right side, which presented
CM enhancement according to curve type V with an
increase of 112% of SI after CM administration suspicious
of breast cancer. Histological evaluation after surgery
revealed an invasive lobular cancer.
Patients who received MRM under HRT (n = 193) showed
highly significant differences in the contribution of the
curve types compared with the patients who were free of
hormone medication at the time of MRM (group D and
group C after withdrawal of HRT) (P < 0.0001). Forty-two
of these 52 patients (80.8%) showed curve type I, 8
patients (15.4%) showed curve type II, and 2 patients
(3.8%) were referred to as curve type III (Fig. 2).
The group of 13 patients who received two MRM examina-
tions during HRT (group B) showed hormonal effects with
comparable signal intensities in both MRI examinations.
Eight patients showed identical curve types in examination
1 and examination 2: six of them showed curve type II, one
of them showed curve type I and one of them showed
curve type III. Three patients were referred to as curve
type II in the first examination and changed to curve type III
in the second MRM session, whereas one patient
changed from curve type III to curve type II and one
patient changed from curve type I to curve type II.
Statistical analysis using the Wilcoxon signed rank test
Figure 1
Five predefined curve types I–V dependent on contrast medium (CM)
enhancement behavior. Curve type I showed a minimal and continuous
increase of postcontrast signal intensity (SI) up to 25%. Curve type II
described a weak continuous increase of postcontrast SI by 25–60%.
A strong enhancement after the injection of CM with a continuous
increase between 60% and 80% is demonstrated by curve type III.
Curve type IV and curve type V represent a very strong increase with a
steep slope of the SI of more than 80% during the first 2 min after CM
administration, followed by a plateau phenomenon with curve type IV
































revealed no significant differences between the two
examinations under HRT (P = 0.375).
Twenty-eight of 30 patients of group C changed to lower
curve types in the second MRM session after withdrawal
of HRT. Twelve patients dropped by two curve types after
withdrawal of HRT (Figs 3 and 4). Sixteen patients
dropped by one curve type after stopping HRT and two
patients remained at curve type II. The Wilcoxon signed
rank test revealed that the curve types under HRT are
highly significant different compared with the curve types
after withdrawal of hormone medication (P < 0.0001).
Discussion
The current study demonstrates bilateral, symmetrical,
synchronous, and progressive CM enhancement in the
breast in dynamic MRM according to the findings of the
majority of the patients receiving HRT. Classifying these
patients in time–SI curve types revealed enhancement
patterns according to curve types I, II, and III that are not
suspicious of malignancy.
The statistically significant difference in curve types with
and without HRT underlines the presence of hormonal
effects in MRM. Neither a plateau phenomenon nor a
washout effect, which are known to be typical for invasive
breast cancer [23], occurred during HRT. In our study
HRT therefore did not result in mimicking breast cancer
typical findings in dynamic MRM. Carcinomas in situ
(CIS), on the contrary, might present with similar findings
to hormonal effects in MRM and therefore may complicate
differential diagnosis. CIS very often have unilateral, focal
formed, local limited, and multifocal signal enhancements.
In cases of bilateral CIS, which is reported to be up to
40% in lobular CIS [24], differentiation may be uncertain.
The detection of CIS may thus be obscured, especially
with low-grade CIS, because they may present with
patchy continuous enhancement just like parenchymal CM
enhancement under HRT in the present study [25].
Stopping HRT prior to a second MRM is thus advisable.
The limitations of the current study are as follows. The
study design was retrospective. The size of the four
patient groups with and without hormonal medication was
therefore different. However, the particular findings of
contrast enhancement were proven statistically significant.
Additionally, the type of hormone medication is rather
heterogeneous (e.g. combination therapy versus mono-
therapy or oral application versus transdermal application).
Figure 2
The contribution of the curve types of patients under hormone
replacement therapy (HRT) (group A; group B, first examination; group
C, first examination; n = 193). Sixty patients (31.1%) showed curve
type I, 88 patients (45.6%) showed curve type II and 45 patients
(23.3%) showed curve type III. These findings were statistically highly
significant (P < 0.0001) compared with patients without hormonal
medication (group C, second examination; group D; n = 52). In the
group free of hormonal medication, 42 patients (80.8%) showed curve
type I, 8 patients (15.4%) showed curve type II and 2 patients (3.8%)

























Magnetic resonance mammography of a 47-year-old patient during
hormone replacement therapy (HRT) and after withdrawal of hormonal
medication. (a) The T1-weighted subtraction image 180 s after
contrast medium (CM) administration showed a bilateral symmetrical
continuous enhancement without a plateau phenomenon or a washout
effect of both breasts. (b) The signal intensity increased by about
75%. The CM enhancement was therefore curve type III. (c) A second
magnetic resonance examination after stopping HRT revealed almost
no visible CM enhancement. (d) Compared with the first magnetic
resonance session during HRT, the time–intensity curve dropped from
type III to type I. R, right; L, left.Reichenbach and colleagues found an elevated
parenchyma/fat tissue ratio in women who were
administered combined hormonal therapy [21]. Growing
volumes of breast parenchyma might be an explanation for
the increase of CM enhancement because breast
parenchyma has a higher microvessel density than fatty
tissue, contributing to extravascular CM passage into the
interstitial space. CM enhancement in malignant tumors
may also be related to an increased fractional volume of
the extravascular extracellular space [26].
Studies of breast cell proliferative activity showed that
most proliferation, as well as the highest breast density on
mammograms, occurs in the luteal phase of the menstrual
cycle, which is partially characterized by high serum levels
of progesterone and estrogens [27]. Breast density is also
increased in HRT [28] and elevated proliferative activity of
breast parenchyma probably results in increased contrast
enhancement during dynamic contrast-enhanced MRI.
Several reports deal with the menstrual cycle and its
effects on relaxation times, breast tissue composition, and
CM enhancement in MRM [15–19]. Graham and
colleagues [23] and Fowler and colleagues [29] found
increased water content and rising fibroglandular tissue
volume of the breast during the end of the menstrual cycle
and the menses. Rieber and colleagues reported an
increase of CM enhancement during the second half of
the menstrual cycle [17]. In this secretory cycle phase, the
levels of estrogene and progesterone are physiologically
elevated. This situation could thus be interpreted as an
endogenous hormonal stimulation, and it seems to have
similar effects on dynamic MRM compared with exogenous
hormone administration. On the contrary, the higher CM
enhancement  during HRT may obscure overlaying
pathologies. However, two cases with histologically proven
cancers demonstrated that the detection of an invasive
cancer or a ductal carcinoma in situ was not obscured
inevitably in these cases.
Kuhl and colleagues found that 26 of 60 enhancing foci
demonstrated enhancement velocity beyond the
malignancy threshold of more than 80% increase of the
signal intensity after the first minute after contrast media
administration [30]. But these cases did not show any
washout effect, which in our opinion is the strongest
indicator for malignancy, and a plateau phenomenon was
present in only two out of 60 lesions. Taking this into
account, the study results are comparable and similar.
However, the few differences between our findings and
other reports may be due to different imaging protocols
because MRM still is not standardized.
Hormonal effects are well known in X-ray mammography
as well and do not similarly affect all women. Breast
density on mammograms during HRT increases in only
20–35% of postmenopausal women [10,11]. In contrast
to MRM, increased breast density in patients under HRT
may even cause a decrease of sensitivity of breast cancer
detection in screening mammography [12,13].
The statistically nonsignificant differences between the
first and the second examination in group B reflect the
equivalence of the two MRM examinations during HRT.
The differences also underline the reproducibility of
enhancement patterns during HRT.
The statistically highly significant differences in group C
indicate that alterations of CM enhancement patterns
caused by HRT are reversible after stopping hormonal
medication, comparable with the cyclic reversible
changes in MRM during the secretory phase of the
menstrual cycle [23].
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Figure 4
Magnetic resonance mammography (MRM) of a 53-year-old patient
during hormone replacement therapy (HRT) with a small histologically
proven invasive lobular cancer in the left breast. (a) The subtraction
image 420 s after contrast medium (CM) administration showed a
bilateral, almost symmetrical, enhancement. (b) The time–intensity
curve of the right breast indicated a continuous rise of the signal
intensity of 41% (curve type II). Additionally, a round blurred area of
stronger CM enhancement was detectable just behind the nipple of
the left breast. The lesion was not obscured by hormone-associated
CM enhancement and showed a rapid CM enhancement followed by a
plateau phenomenon, which is characteristic for curve type IV
suggesting suspicion of malignancy. Eight months after breast-
conserving therapy, a MRM for follow-up was performed without
hormonal medication. (c) The subtraction images showed a weaker
bilateral enhancement. (d) The time–intensity curve indicated a weak
increase of signal intensity less than 25%, reflecting a decrease by one
curve type after withdrawal of HRT. R, right; L, left.Two patients showed higher curve types (curve type III)
during HRT than during treatment with selected estrogene
receptor modulators. These findings again underline that
hormone effects are reversible under selected estrogene
receptor modulator therapy as well, but the patient groups
are too small for statistically proven comparison of
hormone withdrawal and following treatment using
selected estrogene receptor modulators. Bogin and
Degani, in contrast, recently reported higher levels of
vascular endothelial growth factor after treatment with
tamoxifen compared with HRT resulting in higher tumor
vascular permeability, leading to increased CM
enhancement of MCF7 breast cancers. Tumor vessels
seem to behave in a different manner to vessels of normal
breast tissue, which may be due to the pathological high
leakage of tumor vessels [31].
Conclusion
The majority of postmenopausal patients receiving HRT
resulted in characteristic changes with bilateral, symmetrical,
and continuous CM enhancement in dynamic MRM.
Cancer-typical findings like a plateau phenomenon or a
washout effect could not be observed, and in two
examples even breast cancer diagnosis was not affected.
Repeated examinations under HRT resulted in
reproducible hormone effects in MRM, which were
reversible after termination of HRT. In cases of uncertain
suspicious findings, which may be rarely present during
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